| Today’s Big NewsFeb 27, 2024 |
|
| Thursday, March 7, 2024 | 1pm ET / 10am PTJoin us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now. |
|
| By Nick Paul Taylor Pass the mead, because Viking Therapeutics has plenty to celebrate after its dual agonist of GLP-1 and GIP was linked to weight loss of up to 14.7% after 13 weeks of treatment, sending the biotech's stock soaring. |
|
|
|
By Ben Adams It wasn’t supposed to be like this: Eisai and Biogen’s new Alzheimer’s disease drug Leqembi was supposed to be the chosen one after the flop that was Biogen and Eisai’s Aduhelm, but neurologists are voicing “frustration” at core elements of the therapy’s rollout. |
By Gabrielle Masson After a hard few years, biopharma is as lean as ever, with pipelines shaved down so companies can stay afloat. But what if you could hand off a potentially promising second-tier asset while still maintaining rights? |
By Andrea Park In the wake of a recent reminder from the FDA that it still has yet to OK any noninvasive devices to measure blood sugar, Know Labs is ramping up its efforts to change that. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now.
|
|
By Angus Liu More than two years after a high-profile FDA rejection, AstraZeneca has backed out of a collaboration with FibroGen for the latter’s oral anemia drug roxadustat in the U.S. Still, AZ left the partners' China pact intact. |
By Andrea Park Less than three years after debuting on the New York Stock Exchange in an initial public offering, Agiliti is leaving the public market. |
By Fraiser Kansteiner As part of a cost-cutting and restructuring initiative dubbed "Project Energize," Perrigo expects to trim roughly 6% of its total staff, the company said in a fourth-quarter earnings release Tuesday. Perrigo currently employs around 9,000 staffers, according to its website, meaning nearly 550 employees could lose their jobs as part of the corporate overhaul. |
By James Waldron Janux Therapeutics’ executives aren’t the only ones celebrating positive interim phase 1 data from two tumor-focused candidates, with analysts touting their blockbuster potential and investors doubling the biotech’s share price this morning. |
By Zoey Becker The new partner will scale up to a capacity of 50 million doses a year in multi-dose vials that will be ready to buy by 2030, helping Takeda on its mission to produce 100 million doses a year by the end of the decade. |
By Conor Hale Hickey has overseen BD’s portfolio of scientific research tools and testing platforms since January 2021. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
|
|---|
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
